We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Diffusion Pharmaceuticals Inc (DFFN) USD0.001

Sell:$0.34 Buy:$0.35 Change: $0.0265 (7.04%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.0265 (7.04%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.0265 (7.04%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Diffusion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is engaged in the development of therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed. The Company’s product candidate includes Trans Sodium Crocetinate (TSC) and DFN-529. TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. Hypoxia is associated with the pathophysiology of many acute and chronic conditions including cancers, heart attack, stroke, ARDS, skin and soft tissue diseases, neurodegenerative diseases and other intractable and difficult-to-treat conditions, further complicating treatment of the underlying condition by medical providers. The Company completed the first of its three Oxygenation Trials (the TSC TCOM Trial) a Phase I trial. DFN-529, allosteric PI3K/Akt/mTOR pathway inhibitor, is in early-stage development. The Company previously completed two Phase I clinical trials of DFN-529.

Contact details

2020 Avon Ct Ste 4
United States
+1 (434) 2200718

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$37.00 million
Shares in issue:
101.92 million
United States
US dollar

Key personnel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.